Temozolomide in Treatment of Patients With Primary Central Nervous System Lymphoma
Status:
Unknown status
Trial end date:
2019-02-01
Target enrollment:
Participant gender:
Summary
Consolidation treatment for Primary Central Nervous System Diffuse Large B cell
Lymphoma(PCNSL)patients remains to be defined.Here we designed a tolerated treatment of HDMTX
plus Temozolomide,followed by consolidation with Temozolomide in PCNSL patients.
Phase:
Phase 2
Details
Lead Sponsor:
Guangdong General Hospital Guangdong Provincial People's Hospital